United States 119th Congress Status: In Committee Bipartisan · 3 R · 3 D cosponsors

HR 9061 — PREEMPT Act

Last action — Referred to the House Committee on Energy and Commerce.

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed House
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill is in committee in the House. Introduced May 29, 2026. It must pass committee before a floor vote.

Next likely step: a committee vote, then a floor vote in the House.

Odds of enactment

Low chance

Based on the sponsor, cosponsors, and committee posture, this bill has a low chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Advancing 42% · moderate confidence

  • In Committee

    Current position in the legislative process.

  • 6 sponsors

    1 primary, 5 co-sponsors signed on.

  • Bipartisan support

    Sponsored across 2 parties (3 R · 3 D) — cross-party backing.

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

In plain language

The PREEMPT Act addresses energy and commerce regulations.

The PREEMPT Act aims to change certain regulations related to energy and commerce. It is currently under review by the House Committee on Energy and Commerce.

Bill Text

How this bill changes current law

1 change Share ↗

Compared against current U.S. Code AI-generated reading aid — verify against the official bill.

The bill requires the Secretary of Health and Human Services to issue guidance on coverage for preeclampsia screening tests under Medicaid and CHIP.

  • Title XIX of the Social Security Act (42 U.S.C. 1396 et seq.)

    SEC. 1949. GUIDANCE AND TECHNICAL ASSISTANCE WITH RESPECT TO COVERAGE OF PREECLAMPSIA SCREENING AND DETECTION TESTS. (a) Guidance.--Not later than the date that is 180 days after the date of the enactment of this section, the Secretary shall issue guidance to States and, as appropriate, medicaid managed care organizations, on-- (1) best practices for improving outcomes for pregnant women with preeclampsia who are eligible for and receiving medical assistance under a State plan (or waiver of such plan) under this title or a State child health plan (or waiver of such plan) under title XXI through early screening, detection, and management; and (2) which tests for the early detection of preeclampsia may be furnished to such pregnant women as medical assistance under such a State plan (or waiver) or such a State child health plan (or waiver), including whether the biomarker tests described in subsection (c) may be so furnished. (b) Technical Assistance.-- (1) In general.--The Secretary shall, not later than 30 days after receipt of a request from a State for technical assistance with respect to determining whether a State plan or State child health plan may provide medical assistance for a specific test for the early detection of preeclampsia, including a biomarker test described in subsection (c), provide such technical assistance to such State. (2) Rule of construction.--Nothing in this subsection shall be construed as creating a requirement for a State to request or receive the technical assistance described in paragraph (1) as a condition of providing medical assistance for a specific test for the early detection of preeclampsia, or of receiving Federal financial participation for such medical assistance. (c) Biomarker Tests To Be Considered.--For purposes of this section, the Secretary shall consider advanced biomarker tests for the early detection of preeclampsia, including any such test that is regulated and cleared under the Federal Food, Drug, and Cosmetic Act as a device (as defined in section 201(h) of such Act), and any such laboratory-developed testing service furnished by a clinical laboratory that is certified under section 353 of the Public Health Service Act to perform high-complexity testing.

    This establishes a new requirement for guidance and technical assistance on Medicaid and CHIP coverage for preeclampsia screening tests.

Action History

  1. Introduced in House

  2. Introduced in House

  3. Referred to the House Committee on Energy and Commerce.

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 5 co-sponsors · 541 not signed on

Sponsors (1)

Co-sponsors (5)

Not signed on (541)

541 members have not signed on to this bill.

Show all 541 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare labor health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

Who sponsors HR 9061?
HR 9061 is sponsored by Kelly, Robin L. (Democratic), Kiggans, Jennifer A. (Republican), Clarke, Yvette D. (Democratic), Kim, Young (Republican), Gottheimer, Josh (Democratic), and Kean, Thomas H. (Republican).
What is the current status of HR 9061?
This bill is in committee in the House. Introduced May 29, 2026. It must pass committee before a floor vote.
Where can I track HR 9061?
Track HR 9061 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HR 9061

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HR 9061

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →